European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

[1]  Marisa C. Jenkins,et al.  Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. , 2021, JAMA dermatology.

[2]  A. Stenzinger,et al.  Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Jakob Nikolas Kather,et al.  Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. , 2021, European journal of cancer.

[4]  M. Nowicki,et al.  Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring , 2021, International journal of molecular sciences.

[5]  C. Casalou,et al.  Gene expression profiling in melanoma: A view from the clinic. , 2021, Cancer treatment and research communications.

[6]  Yuping Wang,et al.  Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.

[7]  Reena Philip,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors , 2021, Clinical Cancer Research.

[8]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[9]  C. Garbe,et al.  Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients , 2020, Cancers.

[10]  Maria L. Wei,et al.  Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. , 2020, JAMA dermatology.

[11]  V. Andreotti,et al.  The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape , 2020, Frontiers in Molecular Biosciences.

[12]  J. Utikal,et al.  Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Williams,et al.  Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies , 2020, BMJ.

[14]  A. Lallas,et al.  Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring. , 2020, Journal of the American Academy of Dermatology.

[15]  J. Malvehy,et al.  Diagnostic accuracy of imaging studies for initial staging of T2b-T4b melanoma patients. A cross-sectional study. , 2019, Journal of the American Academy of Dermatology.

[16]  E. Weiderpass,et al.  Menopausal Hormone Therapy and Risk of Melanoma: A Nationwide Register-Based Study in Finland , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[17]  C. Garbe,et al.  Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study , 2019, Journal of Immunotherapy for Cancer.

[18]  H. Williams,et al.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. , 2019, The Cochrane database of systematic reviews.

[19]  He-yi Zheng,et al.  Amelanotic melanoma , 2019, Melanoma research.

[20]  I. Zalaudek,et al.  Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. , 2019, Journal of the National Cancer Institute.

[21]  R. Carvajal,et al.  KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development , 2019, American Journal of Clinical Dermatology.

[22]  J. Malvehy,et al.  Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia , 2018, International journal of dermatology.

[23]  J. Malvehy,et al.  Cost‐effectiveness analysis of imaging strategy for an intensive follow‐up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma , 2018, The British journal of dermatology.

[24]  C. Garbe,et al.  Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  T. Kirchhoff,et al.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy , 2018, Journal of the National Cancer Institute.

[26]  H. Williams,et al.  Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. , 2018, The Cochrane database of systematic reviews.

[27]  H. Williams,et al.  Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. , 2018, The Cochrane database of systematic reviews.

[28]  A. Enk,et al.  Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. , 2018, Pathology.

[29]  R. Wolfe,et al.  Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival , 2018, Journal of American Academy of Dermatology.

[30]  C. Berking,et al.  MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. , 2018, European journal of cancer.

[31]  R. Scolyer,et al.  Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond , 2018, Annals of Surgical Oncology.

[32]  S. Swetter,et al.  Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis , 2018, JAMA dermatology.

[33]  A. Lallas,et al.  Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ , 2018, JAMA dermatology.

[34]  A. Gesierich,et al.  Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients , 2018, The British journal of dermatology.

[35]  S. Menzies,et al.  Multiple primary melanoma: a single centre retrospective review , 2017, Melanoma research.

[36]  M. Rajadhyaksha,et al.  Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma , 2017, JAMA dermatology.

[37]  J. Malvehy,et al.  Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study. , 2017, European journal of cancer.

[38]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[39]  G. Ullenhag,et al.  Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. , 2017, European journal of cancer.

[40]  A. Eggermont,et al.  Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[41]  A. Hauschild,et al.  Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[43]  R. Braun,et al.  Incidence trends and clinical–pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the Canton of Zurich, Switzerland , 2017, Melanoma research.

[44]  S. Brennecke,et al.  Melanoma in pregnancy , 2017, Obstetric medicine.

[45]  A. Lallas,et al.  Clinical Indications for Use of Reflectance Confocal Microscopy for Skin Cancer Diagnosis. , 2016, JAMA dermatology.

[46]  J. Malvehy,et al.  Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. , 2016, Journal of the American Academy of Dermatology.

[47]  D. Whiteman,et al.  The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. , 2016, The Journal of investigative dermatology.

[48]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[49]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[50]  R. Porcher,et al.  Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma , 2015, Melanoma research.

[51]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[52]  E. M. Warton,et al.  Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. , 2015, Journal of the American Academy of Dermatology.

[53]  H. Koga,et al.  The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma , 2015, The British journal of dermatology.

[54]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[55]  C. Longo,et al.  Reflectance confocal microscopy as a second‐level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study , 2014, The British journal of dermatology.

[56]  R Hofmann-Wellenhof,et al.  Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety , 2014, The British journal of dermatology.

[57]  L. Thomas,et al.  Selective Use of Sequential Digital Dermoscopy Imaging Allows a Cost Reduction in the Melanoma Detection Process: A Belgian Study of Patients with a Single or a Small Number of Atypical Nevi , 2014, PloS one.

[58]  L. Thomas,et al.  Safety and management of new primary melanomas during receipt of BRAF inhibitors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Hofmann-Wellenhof,et al.  Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions , 2014, The British journal of dermatology.

[60]  A. Eggermont,et al.  Cutaneous melanoma , 2014, The Lancet.

[61]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[62]  L. Layfield,et al.  Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. , 2013, American journal of clinical pathology.

[63]  Shannon C. Trotter,et al.  A Global Review of Melanoma Follow-up Guidelines. , 2013, The Journal of clinical and aesthetic dermatology.

[64]  M. Weichenthal,et al.  Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[65]  M. Tucker,et al.  Dysplastic Nevi and Melanoma , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[66]  J. Kleijnen,et al.  F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review , 2012, Systematic Reviews.

[67]  J. Malvehy,et al.  Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. , 2012, Journal of the American Academy of Dermatology.

[68]  L. Thomas,et al.  Dermoscopy of lentigo maligna melanoma: report of 125 cases , 2012, The British journal of dermatology.

[69]  Josep Malvehy,et al.  Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. , 2012, Journal of the American Academy of Dermatology.

[70]  J. Coebergh,et al.  Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Aitken,et al.  Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  H. Hoekstra,et al.  The current status of S-100B as a biomarker in melanoma. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[73]  A. Armstrong,et al.  Desmoplastic Melanoma , 2020, Definitions.

[74]  R. Braun,et al.  Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. , 2011, Swiss medical weekly.

[75]  I Zalaudek,et al.  Blue‐black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma , 2011, The British journal of dermatology.

[76]  David C Whiteman,et al.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin , 2011, Pigment cell & melanoma research.

[77]  H. Cabo,et al.  Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). , 2011, Archives of dermatology.

[78]  H. Koga,et al.  Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions. , 2011, Archives of dermatology.

[79]  Yan Xing,et al.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. , 2011, Journal of the National Cancer Institute.

[80]  S. Menzies,et al.  Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma , 2011, The Journal of dermatology.

[81]  H. Koga,et al.  Key points in dermoscopic differentiation between early acral melanoma and acral nevus , 2011, The Journal of dermatology.

[82]  H. Koga,et al.  Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia , 2011, The Journal of dermatology.

[83]  Amanda Oakley,et al.  Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas. , 2010, Journal of primary health care.

[84]  P. Nathan,et al.  Revised U.K. guidelines for the management of cutaneous melanoma 2010 , 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[85]  E. Bastiaannet,et al.  Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival , 2010, Annals of Surgical Oncology.

[86]  C. Garbe,et al.  Incisional biopsy and melanoma prognosis: Facts and controversies. , 2010, Clinics in dermatology.

[87]  M. Tucker,et al.  Increased risk of second primary cancers after a diagnosis of melanoma. , 2010, Archives of dermatology.

[88]  S Touzet,et al.  Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population , 2009, The British journal of dermatology.

[89]  Josep Malvehy,et al.  Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. , 2010, European journal of cancer.

[90]  S. Menzies,et al.  Impact of dermoscopy and short‐term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial , 2009, The British journal of dermatology.

[91]  S. Fosså,et al.  Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  A. Marghoob,et al.  The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus. , 2008, Archives of dermatology.

[93]  Riccardo Bono,et al.  Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. , 2008, Archives of dermatology.

[94]  S. Menzies,et al.  Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. , 2008, Archives of dermatology.

[95]  A. Hauschild,et al.  Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. , 2008, Melanoma research.

[96]  A. Hauschild,et al.  Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. , 2008, Melanoma research.

[97]  V. Bataille,et al.  Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues , 2008, Cancer Causes & Control.

[98]  A. Hauschild,et al.  Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. , 2007, Melanoma research.

[99]  J. Grob,et al.  Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report. , 2007, European journal of dermatology : EJD.

[100]  J. Houwing-Duistermaat,et al.  From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. , 2007, Journal of the American Academy of Dermatology.

[101]  Riccardo Bono,et al.  Dermoscopic Features of Difficult Melanoma , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[102]  D. Bishop,et al.  Management of familial melanoma. , 2007, The Lancet. Oncology.

[103]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[104]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Zissimopoulos,et al.  [Serum levels of S-100b protein after four years follow-up of patients with melanoma]. , 2006, Hellenic journal of nuclear medicine.

[106]  Emma Altobelli,et al.  Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy. , 2006, Archives of dermatology.

[107]  S. Menzies,et al.  Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. , 2006, Archives of dermatology.

[108]  Jeffrey E. Lee,et al.  Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  R. Scolyer,et al.  The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma , 2006, Journal of cutaneous pathology.

[110]  H. Haenssle,et al.  Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. , 2006, The Journal of investigative dermatology.

[111]  V. Sondak,et al.  Computed tomography in staging of patients with melanoma metastatic to the regional nodes , 1997, Annals of Surgical Oncology.

[112]  D. Coit,et al.  Computed tomography in evaluation of patients with stage III melanoma , 1997, Annals of Surgical Oncology.

[113]  S. Rosso,et al.  Pregnancy History and Incidence of Melanoma in Women: A Pooled Analysis , 2006, Cancer Causes & Control.

[114]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[115]  A. Halpern,et al.  Clinicopathological features of and risk factors for multiple primary melanomas. , 2005, JAMA.

[116]  J. Grob,et al.  First prospective study of the recognition process of melanoma in dermatological practice. , 2005, Archives of dermatology.

[117]  G. Xing,et al.  Malignant melanoma in pregnancy , 2005, Cancer.

[118]  A. Blum,et al.  Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy , 2005, The British journal of dermatology.

[119]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.

[120]  A. Ahlbom,et al.  Effect of pregnancy on survival in women with cutaneous malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[122]  J. Ajani,et al.  Phase II study of didemnin B in advanced colorectal cancer , 1992, Investigational New Drugs.

[123]  A. Kopf,et al.  Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. , 2004, Journal of the American Academy of Dermatology.

[124]  D. Elder,et al.  Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. , 2003, European journal of cancer.

[125]  C. Garbe,et al.  Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. , 2003, Pigment cell research.

[126]  M. G. Fleming,et al.  Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. , 2003, Journal of the American Academy of Dermatology.

[127]  Lin Fritschi,et al.  Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. , 2003, Journal of the American Academy of Dermatology.

[128]  H. Kittler,et al.  Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. , 2004, Archives of dermatology.

[129]  L. Thomas,et al.  Dermoscopic examination of nail pigmentation. , 2002, Archives of dermatology.

[130]  J. J. van den Oord,et al.  Pathologic staging of melanoma. , 2002, Seminars in oncology.

[131]  Toshiaki Saida,et al.  Dermoscopy for acral pigmented skin lesions. , 2002, Clinics in dermatology.

[132]  W. Stolz,et al.  Dermatoscopy for facial pigmented skin lesions. , 2002, Clinics in dermatology.

[133]  H. Kittler,et al.  Diagnostic accuracy of dermoscopy. , 2002, The Lancet. Oncology.

[134]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  M Landthaler,et al.  Improvement of early recognition of lentigo maligna using dermatoscopy. , 2000, Journal of the American Academy of Dermatology.

[136]  A. Rhodes.  Intervention strategy to prevent lethal cutaneous melanoma: use of dermatologic photography to aid surveillance of high-risk persons. , 1998, Journal of the American Academy of Dermatology.

[137]  J. Grob,et al.  The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. , 1998, Archives of dermatology.

[138]  S. Menzies,et al.  A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma , 1996, Melanoma research.

[139]  H. Soyer,et al.  Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. , 1994, The Journal of investigative dermatology.

[140]  W. Stolz,et al.  The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. , 1994, Journal of the American Academy of Dermatology.

[141]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[142]  J. Grob,et al.  Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma , 1990, Cancer.

[143]  T. Saida.  Malignant Melanoma in Situ on the Sole of the Foot: Its Clinical and Histopathologic Characteristics , 1989, The American Journal of dermatopathology.

[144]  E. Holly,et al.  Number of melanocytic nevi as a major risk factor for malignant melanoma. , 1987, Journal of the American Academy of Dermatology.

[145]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.